5.3 Vasoactive & Inotropic Medication Titration

5.3 Vasoactive & Inotropic Medication Titration

In critical care transport, precise titration of vasoactive and inotropic continuous infusions is vital for restoring tissue perfusion and stabilizing hemodynamics. Understanding receptor pharmacology, cellular mechanisms of action, infusion kinetics, potential toxicities, and concentration conversion formulas is required to prevent life-threatening under- or over-dosing.

---

Receptor Pharmacology Overview

Vasoactive drugs exert clinical actions by binding to specific G-protein-coupled membrane receptors on cardiac myocytes and vascular smooth muscle:

RECEPTOR TARGETS & CELLULAR RESPONSES:

┌──────────┬─────────────────────────────────────┬──────────────────────────────────────────┐
│ Receptor │ Primary Location                    │ Physiological Response                   │
├──────────┼─────────────────────────────────────┼──────────────────────────────────────────┤
│ Alpha-1  │ Vascular Smooth Muscle              │ Vasoconstriction -> Increased SVR & MAP │
│ Beta-1   │ Cardiac Myocytes & SA/AV Nodes      │ Inotropy (+Contractility) & Chronotropy  │
│ Beta-2   │ Vascular & Bronchial Smooth Muscle  │ Vasodilation & Bronchodilation           │
│ Dopamine │ Renal & Splanchnic Vasculature      │ Renal & Splanchnic Vasodilation (D1)     │
│ V1a      │ Vascular Smooth Muscle              │ Non-adrenergic Vasoconstriction          │
└──────────┴─────────────────────────────────────┴──────────────────────────────────────────┘

• $\alpha_1$ Adrenergic: Coupled to $G_q$ proteins. Activation increases intracellular calcium ($IP_3/DAG$ pathway), triggering potent vasoconstriction of arterial and venous smooth muscle.
• $\beta_1$ Adrenergic: Coupled to $G_s$ proteins. Activation stimulates adenylyl cyclase, raising cyclic adenosine monophosphate (cAMP) and intracellular calcium. This yields positive inotropy (contractility), positive chronotropy (heart rate), positive dromotropy (conduction speed), and positive lusitropy (ventricular relaxation).
• $\beta_2$ Adrenergic: Coupled to $G_s$ proteins in vascular and bronchial smooth muscle. Upregulation of cAMP leads to calcium efflux, causing vasodilation and bronchodilation.
• Dopaminergic ($D_1$): Coupled to $G_s$ proteins in renal, mesenteric, coronary, and cerebral vascular beds, promoting vasodilation.
• Vasopressin ($V_{1a}$): Coupled to $G_q$ proteins on vascular smooth muscle. Activation causes direct calcium release and intense vasoconstriction, operating independently of adrenergic receptors.

---

Comprehensive Vasoactive & Inotropic Drug Profiles

1. Norepinephrine (Levophed)

• Receptor Profile: Potent $\alpha_1$ agonist with moderate $\beta_1$ agonist activity ($\alpha_1 ++++, \beta_1 ++$).
• Hemodynamic Effects: Marked systemic vasoconstriction leading to increased SVR and MAP, accompanied by modest inotropic support. Reflex bradycardia often offsets $\beta_1$ chronotropic effects.
• Clinical Indications: First-line vasopressor for septic shock, cardiogenic shock (in combination with Dobutamine), and neurogenic shock.
• Dosing & Titration: Initial 0.02 - 0.05 mcg/kg/min (or $2 - 5\text{ mcg/min}$), titrated by $0.02-0.05\text{ mcg/kg/min}$ every 2-5 minutes to target $\text{MAP} \ge 65\text{ mmHg}$. Standard concentration: $4\text{ mg}$ in $250\text{ mL}$ D5W or NS ($16\text{ mcg/mL}$).

2. Epinephrine (Adrenalin)

• Receptor Profile: Potent agonist across $\beta_1$, $\beta_2$, and $\alpha_1$ receptors.
• Dose-Dependent Receptor Transitions:
  • Low Dose ($0.01 - 0.05\text{ mcg/kg/min}$): Predominant $\beta_1$ and $\beta_2$ stimulation. Increases cardiac output and heart rate while causing mild peripheral vasodilation.
  • High Dose ($> 0.1\text{ mcg/kg/min}$): $\alpha_1$ effects predominate, causing profound systemic vasoconstriction and elevation of MAP.
• Clinical Indications: First-line in anaphylactic shock, cardiac arrest, post-cardiac arrest shock, and severe symptomatic bradycardia refractory to atropine.
• Metabolic Signatures: Epinephrine stimulates hepatic glycogenolysis and skeletal muscle $\beta_2$-receptor Na+/K+-ATPase pumps, causing transient hyperlactatemia and hyperglycemia without tissue hypoxia.
• Dosing: Continuous infusion 0.01 - 0.5 mcg/kg/min titrated to hemodynamic effect.

3. Dopamine

• Receptor Profile: Precursor to norepinephrine exhibiting distinct dose-dependent receptor affinity:

DOPAMINE DOSE-DEPENDENT RECEPTOR SPECTRUM:

  0.5 - 3.0 mcg/kg/min     ===>  D1 Receptor      ---> Renal & Splanchnic Vasodilation
  3.0 - 10.0 mcg/kg/min    ===>  Beta-1 Receptor  ---> Increased Contractility & HR
 10.0 - 20.0 mcg/kg/min    ===>  Alpha-1 Receptor ---> Systemic Vasoconstriction

• Clinical Considerations: Dopamine triggers significant endogenous norepinephrine release. It carries high risks of tachyarrhythmias (atrial fibrillation, VT) compared to Norepinephrine. Low-dose "renal dose" dopamine does NOT provide renal protection or prevent acute kidney injury and is no longer recommended.

4. Phenylephrine (Neo-Synephrine)

• Receptor Profile: Pure, selective $\alpha_1$ agonist ($\alpha_1 ++++$, no $\beta$ activity).
• Hemodynamic Effects: Produces arterial vasoconstriction, raising SVR and MAP without direct cardiac inotropic or chronotropic stimulation. Induces reflex bradycardia and can decrease stroke volume in patients with baseline LV dysfunction.
• Clinical Indications: Hyperdynamic septic shock with severe tachycardia, anesthesia-induced hypotension, or neurogenic shock.
• Dosing: 0.5 - 5.0 mcg/kg/min (or $20 - 200\text{ mcg/min}$).

5. Vasopressin (Pitressin)

• Receptor Profile: Selective $V_{1a}$ receptor agonist.
• Hemodynamic Effects: Direct vascular smooth muscle vasoconstriction. Operates effectively in severe acidosis and catecholamine-refractory shock where adrenergic receptors are desensitized.
• Clinical Indications: Adjuvant vasopressor in septic shock to reduce norepinephrine dosage requirements ("norepinephrine-sparing effect") and in vasodilatory shock.
• Dosing: Administered as a fixed, non-titrated infusion of 0.03 units/min (or $0.01-0.04\text{ units/min}$). Never titrate rapidly due to risks of intestinal and myocardial ischemia.

6. Dobutamine (Dobutrex)

• Receptor Profile: Synthetic catecholamine with potent $\beta_1$ agonist and mild $\beta_2$ agonist activity ($\beta_1 ++++, \beta_2 ++$).
• Hemodynamic Effects: Significant positive inotropy and chronotropy with mild vascular smooth muscle dilation. Increases Cardiac Output and Stroke Volume while reducing PAWP and SVR.
• Clinical Indications: Severe decompensated heart failure and cardiogenic shock (often paired with Norepinephrine to offset vasodilation).
• Dosing: 2.5 - 20.0 mcg/kg/min.

7. Milrinone (Primacor)

• Receptor Profile: Non-adrenergic Phosphodiesterase-3 (PDE3) Inhibitor.
• Mechanism of Action: Inhibits PDE3 enzymes in cardiac myocytes and vascular smooth muscle, preventing breakdown of cyclic AMP (cAMP). High cAMP levels increase intracellular calcium in myocytes (enhancing contractility) while accelerating calcium uptake in vascular smooth muscle (causing relaxation).
• Hemodynamic Effects: Known as an "Inodilator". Increases Cardiac Index while markedly reducing PAWP, CVP, SVR, and Pulmonary Vascular Resistance (PVR). Does not increase myocardial oxygen consumption to the same extent as beta-agonists.
• Elimination & Kinetics: Renally eliminated with a long elimination half-life ($2 - 4\text{ hours}$). Requires dose reductions in renal failure ($CrCl < 50\text{ mL/min}$). IV loading boluses ($50\text{ mcg/kg}$) are typically omitted in critical transport to prevent sudden hypotension.
• Dosing: Continuous infusion 0.125 - 0.75 mcg/kg/min.

8. Sodium Nitroprusside (Nipride)

• Mechanism of Action: Direct nitric oxide (NO) donor causing immediate relaxation of vascular smooth muscle in both arteries and veins.
• Hemodynamic Effects: Balanced arterial and venous vasodilation. Decreases SVR (afterload) and PAWP/CVP (preload), reducing cardiac workload.
• Clinical Indications: Hypertensive emergencies, acute aortic dissection, and acute mitral regurgitation.
• Cyanide & Thiocyanate Toxicity Risks:
  • Sodium Nitroprusside contains five cyanide groups per molecule. Metabolism by hemoglobin releases free cyanide.
  • Cyanide Toxicity: Free cyanide binds to ferric iron ($Fe^{3+}$) in mitochondrial cytochrome oxidase, shutting down oxidative phosphorylation and cellular respiration. Presents as unexplained metabolic acidosis, elevated serum lactate, and elevated SvO2 (cells cannot extract oxygen). Treatment: Hydroxocobalamin (Cyanokit) or Sodium Thiosulfate.
  • Thiocyanate Toxicity: Occurs during prolonged infusions ($> 48\text{ hours}$) or renal impairment. Presents with confusion, hyperreflexia, tinnitus, and seizures.
• Administration Rule: Must be protected from light using amber light-blocking sleeves.
• Dosing: 0.25 - 10.0 mcg/kg/min.

9. Nitroglycerin (Tridil)

• Mechanism of Action: Direct nitric oxide donor acting primarily on venous capacitance vessels at lower doses ($< 50\text{ mcg/min}$) to reduce preload (PAWP/CVP). At higher doses ($> 100-200\text{ mcg/min}$), causes arterial vasodilation, reducing afterload.
• Clinical Indications: Acute Coronary Syndromes, acute cardiogenic pulmonary edema, and hypertensive crisis.
• Special Considerations: Requires non-PVC glass or polyethylene IV tubing to prevent drug adsorption into plastic matrix. Tachyphylaxis (tolerance) develops within 24-48 hours.
• Dosing: 5 - 200 mcg/min.

---

Infusion Calculation Formulas & Conversions

Critical care paramedics must execute rapid, error-free drug concentration and infusion rate calculations.

1. Concentration Formula

$$\text{Concentration (mcg/mL)} = \frac{\text{Total Drug Amount (mg)} \times 1000\text{ mcg/mg}}{\text{Total Volume (mL)}}$$

Example: $4\text{ mg}$ Norepinephrine in $250\text{ mL}$ D5W $= \frac{4000\text{ mcg}}{250\text{ mL}} = 16\text{ mcg/mL}$.

2. Weight-Based Infusion Rate Formula (mL/hr)

$$\text{Rate (mL/hr)} = \frac{\text{Dose (mcg/kg/min)} \times \text{Weight (kg)} \times 60\text{ min/hr}}{\text{Concentration (mcg/mL)}}$$

Worked Calculation Example: Patient weight $= 80\text{ kg}$. Ordered dose $= 0.1\text{ mcg/kg/min}$ Norepinephrine. Concentration $= 16\text{ mcg/mL}$.

$$\text{Rate} = \frac{0.1\text{ mcg/kg/min} \times 80\text{ kg} \times 60\text{ min/hr}}{16\text{ mcg/mL}} = \frac{480\text{ mcg/hr}}{16\text{ mcg/mL}} = 30\text{ mL/hr}$$

3. Non-Weight-Based Infusion Rate Formula (mL/hr)

$$\text{Rate (mL/hr)} = \frac{\text{Dose (mcg/min)} \times 60\text{ min/hr}}{\text{Concentration (mcg/mL)}}$$

Worked Calculation Example: Ordered dose $= 40\text{ mcg/min}$ Nitroglycerin. Concentration $= 50\text{ mg}$ in $250\text{ mL}$ ($200\text{ mcg/mL}$).

$$\text{Rate} = \frac{40\text{ mcg/min} \times 60\text{ min/hr}}{200\text{ mcg/mL}} = \frac{2400\text{ mcg/hr}}{200\text{ mcg/mL}} = 12\text{ mL/hr}$$